Inflammation-related prognostic markers in resected hepatocellular carcinoma.
Fiche publication
Date publication
décembre 2023
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Dr LUPBERGER Joachim, Pr PESSAUX Patrick
Tous les auteurs :
Giannone F, Slovic N, Pessaux P, Schuster C, Baumert TF, Lupberger J
Lien Pubmed
Résumé
Hepatocellular carcinoma is usually detected late and therapeutic options are unsatisfactory. Despite marked progress in patient care, HCC remains among the deadliest cancers world-wide. While surgical resection remains a key option for early-stage HCC, the 5-year survival rates after surgical resection are limited. One reason for limited outcomes is the lack of reliable prognostic biomarkers to predict HCC recurrence. HCC prognosis has been shown to correlate with different systemic and pathological markers which are associated with patient survival and HCC recurrence. Liver inflammatory processes offer a large variety of systemic and pathological markers which may be exploited to improve the reliability of prognosis and decision making of liver surgeons and hepatologists. The following review aims to dissect the potential tools, targets and prognostic meaning of inflammatory markers in patients with resectable HCC. We analyze changes in circulant cellular populations and assess inflammatory biomarkers as a surrogate of impaired outcomes and provide an overview on predictive gene expression signatures including inflammatory transcriptional patterns, which are representative of poor survival in these patients.
Mots clés
HCC, biomarkers, genetic signatures, inflammation, patient outcome
Référence
Front Oncol. 2023 12 7;13:1267870